Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Saccharomyces cerevisiae

PROVIDER: GSE160539 | GEO | 2021/06/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast.

Project description:Most eukaryotic mRNAs accommodate alternative sites of poly(A) addition in the 3' untranslated region in order to regulate mRNA function. Here, we present a systematic analysis of 3' end formation factors, which revealed 3'UTR lengthening in response to a loss of the core machinery, whereas a loss of the Sen1 helicase resulted in shorter 3'UTRs. We show that the anti-cancer drug cordycepin, 3' deoxyadenosine, caused nucleotide accumulation and the usage of distal poly(A) sites. Mycophenolic acid, a drug which reduces GTP levels and impairs RNA polymerase II (RNAP II) transcription elongation, promoted the usage of proximal sites and reversed the effects of cordycepin on alternative polyadenylation. Moreover, cordycepin-mediated usage of distal sites was associated with a permissive chromatin template and was suppressed in the presence of an rpb1 mutation, which slows RNAP II elongation rate. We propose that alternative polyadenylation is governed by temporal coordination of RNAP II transcription and 3' end processing and controlled by the availability of 3' end factors, nucleotide levels and chromatin landscape.

| S-EPMC8263057 | biostudies-literature

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - cordycepin treatment

Project description:PAT-seq approach was used to determine changes to 3'UTR length in yeast upon addition of 20µg/ml cordycepin (3'deoxyadenosine) for 0, 5, 10, 20 or 40 minutes

2021-06-25 | GSE160537 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - NNS complex

Project description:PAT-seq approach was used to determine changes to 3'UTR length in yeast upon mutation of NNS subunits Nrd1 (nrd1-5), Nab3 (nab3-11) and Sen1 (sen1-1) compared to wild type cells

2021-06-25 | GSE160567 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - 4tU cordycepin treatment

Project description:mPAT approach using an anchored oligo-dT (TV12VN) primer to determine changes to 3'UTR length in yeast upon cordycepin treatment and new transcription using 4-thiouracil (4tU) labelling of RNA. This appears as a T to C conversion in sequencing reads.

2021-06-25 | GSE160993 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - 3'end cleavage factors

Project description:PAT-seq approach was used to determine changes to 3'UTR length in yeast upon mutation of the core cleavage and polyadenylation subunits Rna14 (rna14-1), Pcf11 (pcf11-2), Clp1 (clp1-K136A-T137A), Hrp1/Nab4 (Nab4-1), Ysh1 (ysh1-13), Fip1 (fip1-1) and Pap1 (pap1-1) compared to wild type cells

2021-06-25 | GSE160538 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - 3'end cleavage factor mPAT

Project description:mPAT approach was used to determine changes to 3'UTR length in yeast upon mutation of cleavage and polyadenylation factor subunits compared to wild type cells

2021-06-25 | GSE160995 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - 4tU cordycepin treatment with rpb1 slow mutant

Project description:mPAT approach using an anchored oligo-dT (TV12VN) primer to determine changes to 3'UTR length in yeast with a slow RNA polymerase II mutant rpb1-1, complemented with wild-type RPB1 or a slow rpb1 mutant plasmid, upon cordycepin treatment and new transcription using 4-thiouracil (4tU) labelling of RNA. This appears as a T to C conversion in sequencing reads.

2021-06-25 | GSE160994 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast

Project description:Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast

| PRJNA673491 | ENA

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - cordycepin treatment

Project description:Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - cordycepin treatment

| PRJNA673492 | ENA

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - NNS complex

Project description:Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - NNS complex

| PRJNA673618 | ENA